Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL TOFACITINIB MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL TOFACITINIB MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL TOFACITINIB MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MARKET OVERVIEW
4.1 DRIVERS
4.2 RESTRAINS
4.3 OPPURTUNITY
4.4 CHALLENGES
5 PREMIUM INSIGHTS
5.1 PORTER'S 5 FORCES
5.2 PESTEL ANALYSIS
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL TOFACITINIB MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL TOFACITINIB MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDIACTION
11.3 PHARACOLOGICAL CLASS OD THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 PACKAGING TYPE
11.1 DRUG ROUTE OF ADMINISTRATION
11.11 DOSING FREQUENCY
11.12 DRUG INSIGHT
11.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.13.1 FORECAST MARKET OUTLOOK
11.13.2 CROSS COMPETITION
11.13.3 THERAPEUTIC PORTFOLIO
11.13.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 GLOBAL TOFACITINIB MARKET, BY DOSAGE FORM
(MARKET SHARE, VOLUME & ASP ANALYSIS WILL BE PROVIDED FOR ALL PRODUCTS)
14.1 OVERVIEW
14.2 TABLET
14.2.1 BY TYPE
14.2.1.1. IMMEDIATE RELEASE
14.2.1.1.1. MARKET SIZE (USD)
14.2.1.1.2. MARKET VOLUME (UNIT)
14.2.1.1.3. AVERAGE SELLING PRICE (USD)
14.2.1.2. EXTENDED RELEASE
14.2.2 BY THERAPY
14.2.2.1. MONOTHERAPY
14.2.2.2. COMBINATION THERAPY
14.2.2.2.1. METHOTREXATE
14.2.2.2.2. CICLOSPORIN
14.2.2.2.3. CYCLOPHOSPHAMIDE
14.2.2.2.4. OTHERS
14.2.3 BY DOSE
14.2.3.1. 5MG
14.2.3.2. 10MG
14.2.3.3. 20 MG
14.2.3.4. OTHERS
14.3 ORAL SOLUTION
14.3.1 BY THERAPY
14.3.1.1. MONOTHERAPY
14.3.1.2. COMBINATION THERAPY
14.3.1.2.1. METHOTREXATE
14.3.1.2.2. CICLOSPORIN
14.3.1.2.3. CYCLOPHOSPHAMIDE
14.3.1.2.4. OTHERS
15 GLOBAL TOFACITINIB MARKET, BY INDICATION
15.1 OVERVIEW
15.2 RHEUMATOID ARTHRITIS
15.3 PSORIATIC ARTHRITIS
15.4 ANKYLOSING SPONDYLITIS
15.5 ALLERGIC RHINITIS
15.6 ULCERATIVE COLITIS
15.7 POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
15.8 COVID19
15.9 OTHERS
16 GLOBAL TOFACITINIB MARKET, BY PATIENT TYPE
16.1 OVERVIEW
16.2 CHILD
16.2.1 MALE
16.2.2 FEMALE
16.3 ADULT
16.3.1 MALE
16.3.2 FEMALE
16.4 GERIATRIC
16.4.1 MALE
16.4.2 FEMALE
17 GLOBAL TOFACITINIB MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITAL
17.3 CLINICS
17.4 HOME HEALTHCARE
17.5 SPECIALITY CENTER
17.6 AMBULTORY CENTERS
17.7 OTHERS
18 GLOBAL TOFACITINIB MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 ONLINE PHARMACY
18.4 RETAIL PHARMACY
18.5 OTHERS
19 GLOBAL TOFACITINIB MARKET, BY GEOGRAPHY
19.1 GLOBAL TOFACITINIB MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.2 NORTH AMERICA
19.2.1 U.S.
19.2.1.1. U.S. TOFACITINIB MARKET, BY DOSAGE FORM
19.2.1.2. U.S. TOFACITINIB MARKET, BY INDICATION
19.2.1.3. U.S. TOFACITINIB MARKET, BY PATIENT TYPE
19.2.1.4. U.S. TOFACITINIB MARKET, BY END USER
19.2.1.5. U.S. TOFACITINIB MARKET, BY DISTRIBUTION CHANNEL
19.2.2 CANADA
19.2.3 MEXICO
19.3 EUROPE
19.3.1 GERMANY
19.3.2 FRANCE
19.3.3 U.K.
19.3.4 HUNGARY
19.3.5 LITHUANIA
19.3.6 AUSTRIA
19.3.7 IRELAND
19.3.8 NORWAY
19.3.9 POLAND
19.3.10 ITALY
19.3.11 SPAIN
19.3.12 RUSSIA
19.3.13 TURKEY
19.3.14 NETHERLANDS
19.3.15 SWITZERLAND
19.3.16 REST OF EUROPE
19.4 ASIA-PACIFIC
19.4.1 JAPAN
19.4.2 CHINA
19.4.3 SOUTH KOREA
19.4.4 INDIA
19.4.5 AUSTRALIA
19.4.6 SINGAPORE
19.4.7 THAILAND
19.4.8 MALAYSIA
19.4.9 INDONESIA
19.4.10 PHILIPPINES
19.4.11 VIETNAM
19.4.12 REST OF ASIA-PACIFIC
19.5 SOUTH AMERICA
19.5.1 BRAZIL
19.5.2 ARGENTINA
19.5.3 PERU
19.5.4 REST OF SOUTH AMERICA
19.6 MIDDLE EAST AND AFRICA
19.6.1 SOUTH AFRICA
19.6.2 SAUDI ARABIA
19.6.3 UAE
19.6.4 EGYPT
19.6.5 KUWAIT
19.6.6 ISRAEL
19.6.7 REST OF MIDDLE EAST AND AFRICA
19.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
20 GLOBAL TOFACITINIB MARKET, SWOT AND DBMR ANALYSIS
21 GLOBAL TOFACITINIB MARKET, COMPANY LANDSCAPE
21.1 COMPANY SHARE ANALYSIS: GLOBAL
21.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
21.3 COMPANY SHARE ANALYSIS: EUROPE
21.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21.5 MERGERS & ACQUISITIONS
21.6 NEW PRODUCT DEVELOPMENT & APPROVALS
21.7 EXPANSIONS
21.8 REGULATORY CHANGES
21.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
22 GLOBAL TOFACITINIB MARKET, COMPANY PROFILE
22.1 MARKETED PRODUCTS
22.1.1 PFIZER INC.
22.1.1.1. COMPANY OVERVIEW
22.1.1.2. REVENUE ANALYSIS
22.1.1.3. GEOGRAPHIC PRESENCE
22.1.1.4. PRODUCT PORTFOLIO
22.1.1.5. RECENT DEVELOPMENTS
22.2 EMERGING AND PIPELINE COMPANIES AND SUPPLIER
22.2.1 BRECKENRIDGE PHARMS
22.2.1.1. COMPANY OVERVIEW
22.2.1.2. REVENUE ANALYSIS
22.2.1.3. GEOGRAPHIC PRESENCE
22.2.1.4. PRODUCT PORTFOLIO
22.2.1.5. RECENT DEVELOPMENTS
22.2.2 MICRO LABS LTD.
22.2.2.1. COMPANY OVERVIEW
22.2.2.2. REVENUE ANALYSIS
22.2.2.3. GEOGRAPHIC PRESENCE
22.2.2.4. PRODUCT PORTFOLIO
22.2.2.5. RECENT DEVELOPMENTS
22.2.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.2.3.1. COMPANY OVERVIEW
22.2.3.2. REVENUE ANALYSIS
22.2.3.3. GEOGRAPHIC PRESENCE
22.2.3.4. PRODUCT PORTFOLIO
22.2.3.5. RECENT DEVELOPMENTS
22.2.4 PRINSTON PHARMACEUTICAL INC.
22.2.4.1. COMPANY OVERVIEW
22.2.4.2. REVENUE ANALYSIS
22.2.4.3. GEOGRAPHIC PRESENCE
22.2.4.4. PRODUCT PORTFOLIO
22.2.4.5. RECENT DEVELOPMENTS
22.2.5 ZYDUS
22.2.5.1. COMPANY OVERVIEW
22.2.5.2. REVENUE ANALYSIS
22.2.5.3. GEOGRAPHIC PRESENCE
22.2.5.4. PRODUCT PORTFOLIO
22.2.5.5. RECENT DEVELOPMENTS
22.2.6 BEACON PHARMACEUTICALS PLC
22.2.7 ESTEVE
22.2.7.1. COMPANY OVERVIEW
22.2.7.2. REVENUE ANALYSIS
22.2.7.3. GEOGRAPHIC PRESENCE
22.2.7.4. PRODUCT PORTFOLIO
22.2.7.5. RECENT DEVELOPMENTS
22.2.8 GLOBE PHARMACEUTICALS LTD.
22.2.8.1. COMPANY OVERVIEW
22.2.8.2. REVENUE ANALYSIS
22.2.8.3. GEOGRAPHIC PRESENCE
22.2.8.4. PRODUCT PORTFOLIO
22.2.8.5. RECENT DEVELOPMENTS
22.2.9 DELTA PHARMA LIMITED
22.2.9.1. COMPANY OVERVIEW
22.2.9.2. REVENUE ANALYSIS
22.2.9.3. GEOGRAPHIC PRESENCE
22.2.9.4. PRODUCT PORTFOLIO
22.2.9.5. RECENT DEVELOPMENTS
22.2.10 INTAS
22.2.10.1. COMPANY OVERVIEW
22.2.10.2. REVENUE ANALYSIS
22.2.10.3. GEOGRAPHIC PRESENCE
22.2.10.4. PRODUCT PORTFOLIO
22.2.10.5. RECENT DEVELOPMENTS
22.2.11 APRAZER
22.2.11.1. COMPANY OVERVIEW
22.2.11.2. REVENUE ANALYSIS
22.2.11.3. GEOGRAPHIC PRESENCE
22.2.11.4. PRODUCT PORTFOLIO
22.2.11.5. RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23 RELATED REPORTS
24 CONCLUSION
25 QUESTIONNAIRE
26 ABOUT DATA BRIDGE MARKET RESEARCH
